查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1557331

病毒载体製造市场－2024年至2029年预测

Viral Vector Manufacturing Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

病毒载体製造市场预计将从2024年的1,192,033,000美元成长到2029年的2,612,384,000美元，复合年增长率为16.99%。

病毒载体製造涉及重要载体的开发，例如用于运输治疗基因的腺病毒载体、慢病毒载体和逆转录病毒载体。由于其高性能，病毒载体已应用于基因治疗和疫苗治疗。这些应用的成长也推动了对病毒载体的需求，从而提高了整体製造水准。

此外，病毒载体也用于治疗多种疾病，包括心血管疾病、各种癌症、感染疾病和代谢疾病。因此，临床试验数量的增加和对有效疾病治疗方法的认识不断增强，预计将在预测期内进一步推动病毒载体製造市场的成长。

由于技术和平台的复杂性，载体设计、生产、包装和发布测试都受到限制且具有挑战性。因此，该领域的许多参与者经常寻求涵盖多个方面的策略联盟和收购，例如提供临床级产品，以成功共同开发基于病毒製剂的产品。

此外，有效表达治疗基因的能力和非致病性也是推动该市场成长的因素。预计推动市场成长的其他主要因素包括生物製药生产投资的增加以及人口老化的加剧、医疗保健支出和技术进步（特别是在基因工程领域）。

此外，由于全球疾病负担增加，医疗保健设施的便利性增加以及疾病治疗需求的增加也是预测期内推动该市场成长的一些因素。然而，这个利基产业向大规模生产的转变是在一定程度上抑制市场成长的因素之一。

病毒载体製造市场驱动因素：

  • 治疗学方面的有利投资预计将增加对病毒载体的需求。

携带遗传讯息的病毒载体可以直接针对疾病，进而改变细胞功能。由于这些优点，载体在基因治疗中得到了广泛的应用，它们将健康的基因拷贝传递到细胞中。癌症、心血管疾病和神经退化性疾病的盛行率日益增加，导致了基因治疗开发的各种研究合作和投资。

例如，2023年8月，Astella Pharma Inc.和Poseida Therapeutics宣布进行5,000万美元策略性投资，以支持后者在癌细胞治疗方面的进展。这项投资将使 Astera 能够进一步专注于开发下一代免疫肿瘤药物。

同样，2023年11月，Astra Zeneca与 Cellectis 签订了合作和投资协议，以加强免疫学、肿瘤学和罕见疾病领域下一代疗法的开发。根据此次合作，Astra Zeneca将利用 Intelis 的基因编辑技术开发新型细胞和基因疗法。

  • 疫苗开发设施的持续建设进一步推动了整体市场的扩张。

全球感染疾病的规模不断扩大，对各种有效疫苗来对抗它们的需求也不断增加。例如，BioNtech SE于2022年6月宣布将在卢安达建立mRNA疫苗生产设施。

同样，2024 年 7 月，美国卫生与公共服务部宣布向 Moderna 提供约 1.76 亿美元，用于开发基于 mRNA 的流感疫苗。这项投资是透过 BARDA（生物医学高级研究与开发局）新成立的快速反应合作伙伴汽车联盟宣布的。

病毒载体製造市场地理前景

  • 据估计，北美将占据很大的市场份额。

按地区划分，北美地区有望显着成长。在美国和加拿大主要新兴市场开发并核准新疫苗和基因疗法开发后，由于持续的治疗学合作研究，预计该地区将占据重要的市场占有率。

例如，2023年12月，美国食品药物管理局核准了两种基于细胞的基因疗法Casgevy和Lyfgenia，用于治疗12岁及以上的镰状细胞患者。这种治疗方法代表了基因疗法的革命性进步，并将改善影响近 10 万美国人的镰状细胞疾病的治疗。

同样，2023 年 10 月，纽约州州长宣布投资 9,800 万美元，扩大罗斯威尔公园综合癌症中心的基因治疗研发业务。此次扩建将使罗斯威尔公园成为纽约第一个基因治疗中心，并符合政府在生命科学领域实现新里程碑的承诺。

此外，美国政府也投资扩大医疗设施和研究机构，以加强对各种慢性疾病的治疗，这对病毒载体的需求有正面影响。此外，辉瑞、佳乐士、Astra Zeneca等大型製药公司的进驻也为未来的市场拓展铺平了道路。

2024年2月，Astra Zeneca宣布斥资3亿美元在罗克维尔建立最先进的设施，用于开发以T细胞治疗为中心的商业细胞治疗平台。该设施还将促进未来重要的癌症临床试验，以促进癌症治疗的进步。

病毒载体製造的主要市场开拓

  • 2024 年 2 月，新南威尔斯州政府成立了一家商业公司，在 Westmead 经营病毒载体生产设施。近1.345亿美元已投入生产用于临床和研究试验的病毒载体产品，该机构将确保政府的长期病毒载体生产运作。
  • 2022 年 6 月，Avid Bioservices, Inc. 在其 Current Good Manufacturing Plant (CG Plant) 製造工厂运作了新的病毒载体开发、分析和製程开发套件。
  • 2022 年 5 月，AGC Biologics 宣布增加病毒载体悬浮技术和製造能力，以支持其位于科罗拉多州朗蒙特的商业级园区的基因疗法开发和製造。

病毒载体製造市场区隔与分析如下：

按类型

  • 逆转录病毒载体
  • 慢病毒载体
  • 腺病毒载体
  • 其他的

按用途

  • 疫苗学
  • 基因治疗

按最终用户

  • 製药和生物技术公司
  • 研究所
  • 受託研究机构

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 其他中东/非洲
  • UAE
  • 沙乌地阿拉伯
  • 其他的
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 泰国
  • 印尼
  • 台湾
  • 其他的

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章病毒载体製造市场：依类型

  • 介绍
  • 逆转录病毒载体
  • 慢病毒载体
  • 腺病毒载体
  • 其他的

第六章病毒载体製造市场：依应用分类

  • 介绍
  • 疫苗学
  • 基因治疗

第七章病毒载体製造市场：依最终用户分类

  • 介绍
  • 製药和生物技术公司
  • 研究所
  • 合约研究组织

第八章病毒载体製造市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 泰国
    • 印尼
    • 台湾
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Sirion-Biotech GmbH
  • Vigene Biosciences
  • Batavia Biosciences BV
  • Virovek
  • Lonza
  • Vector Biolabs
  • Cobra Biologics
  • MaxCyte, Inc.
  • Genelux
  • BioNTech SE
简介目录
Product Code: KSI061611919

The viral vector manufacturing market is poised to grow to US$2,612.384 million in 2029 from US$1,192.033 million in 2024 at a CAGR of 16.99%.

Viral vector manufacturing involves developing crucial carriers such as adenoviral vectors, lentiviral vectors, and retroviral vectors used to transport therapeutic genes. Owing to their high-performance benefits, viral vectors find applicability in gene therapy and vaccinology. It also bolstered growth in such applications, which is majorly driving the demand for viral vectors, thereby propelling their overall manufacturing level.

Moreover, viral vectors have been utilized to treat a variety of diseases that are inclusive of but not limited to cardiovascular diseases, different types of cancer, hematologic, infectious, and metabolic diseases. Hence, the growing number of clinical trials and the expanding cognizance of effective modes of disease treatment are further expected to drive the viral vector manufacturing market growth during the forecast period.

Vector designing, production, packaging, and release testing are subject to limited availability and challenges due to the complex nature of technologies and platforms. Hence, many players in this space frequently seek strategic collaborations and acquisitions that cover many aspects, such as the delivery of clinal grade products, to facilitate the successful collaboration development of viral agent-based products.

Moreover, the efficient ability to express the therapeutic genes and their non-pathogenic nature is another factor responsible for driving this market's growth. The other key factors expected to drive the market's growth are the increasing investment in biopharmaceutical production coupled with the growing aging population, healthcare expenditure, and technological advancement, especially in the genetic engineering segment.

Furthermore, the increasing accessibility of healthcare facilities and the growing demand for disease treatment due to the increasing global burden of diseases are a few of the other factors poised to drive the growth of this market during the forecast period. Nevertheless, the transition of this niche industry to high manufacturing is one such factor that may restrain the market's growth to a certain extent.

Viral Vector Manufacturing Market Drivers:

  • Favorable investments in therapeutics are expected to bolster the demand for viral vectors.

Viral vectors with genetic information can directly target the disease, thereby altering cell functioning. Due to such benefits, vectors find high applicability in gene therapy to assist in delivering a healthy copy of a gene in the cell. The growing prevalence of cancer, cardiovascular, and neurodegenerative disease has led to various research collaborations and investments in gene and therapeutic therapies development.

For instance, in August 2023, Astella Pharma Inc. and Poseida Therapeutics announced a strategic investment of US$50 million to support the latter's advancements in cancer cell therapy. This investment would also further Astella's focus on developing next-generation immune-oncology drugs.

Likewise, in November 2023, AstraZeneca formed a collaboration and an investment agreement with Cellectis to bolster next-generation therapeutics development in immunology, oncology, and rare disease fields. Under the collaboration, AstraZeneca would leverage Cellectis gene editing technologies for developing novel cell & gene therapy products.

  • The ongoing establishment of vaccine development facilities has furthered the overall market expansion.

The scale of infectious disease globally is on the rise, and to combat it, the demand for various effective vaccines is also growing, which has led to the establishment of new vaccine manufacturing facilities in major economies. For instance, in June 2022, BioNtech SE announced the establishment of an mRNA vaccine production facility in Rwanda, which would provide all manufactured vaccines in member states of the African Union.

Likewise, in July 2024, the U.S. Department of Health and Human Services announced the provision of nearly US$176 million to Moderna for developing an mRNA-based influenza vaccine. The investment was announced through BARDA's (Biomedical Advanced Research and Development Authority) new Rapid Response Partnership Vehicle Consortium.

Viral Vector Manufacturing Market Geographical Outlook

  • North America is estimated to account for a remarkable share of the market.

Region-wise, the North American region is poised for significant growth. It will account for a considerable market share fuelled by the ongoing research collaboration for therapeutics followed by the development and approval of new vaccine & gene therapy development in major regional nations, namely the United States and Canada.

For instance, in December 2023, the Food and Drug Administration approved two-cell-based gene therapies, "Casgevy" and "Lyfgenia", for treating sickle cell disease in 12-year-old and older patients. The therapies signal an innovative advancement in gene therapy and will improve the treatment of sickle cell disease, which affects nearly 100,000 Americans.

Likewise, in October 2023, the Governor of New York announced an investment of US$98 million to expand the gene therapy-related research & development operations at the Roswell Park Comprehensive Cancer Center. This expansion would make Roswell New York's first gene therapy hub and also comply with the government's commitment to achieve new milestones in the life science sector.

Additionally, the US government is also investing in healthcare facilities and research institutes expansion to bolster the treatment of various chronic diseases, which has positively impacted the demand for viral vectors. Moreover, the well-established presence of major pharmaceutical companies, namely Pfizer, Galax Smith Kline, and AstraZeneca, has paved the way for future market expansion.

In February 2024, AstraZeneca announced an investment of US$300 million in establishing its state-of-the-art facility in Rockville to develop commercial cell therapy platforms, mainly on T-cell therapies. The facility will also facilitate critical cancer trials in the future to bolster the advancement in cancer treatment.

Viral Vector Manufacturing Key Market Developments

  • In February 2024, the New South Wales government established a commercial company to operate its viral vector manufacturing facility in Westmead. This establishment would ensure the government's long-term run in viral vector manufacturing since it has already committed nearly $134.5 million to manufacture viral vector products for clinical and research trials.
  • In June 2022, Avid Bioservices, Inc. inaugurated the analytical and process development suites in the company's new viral vector development and Current Good Manufacturing Plant manufacturing facility. The viral vector facility's CGMP manufacturing suites were set up online by mid-2023.
  • In May 2022, AGC Biologics announced the addition of the viral vector suspension technology and capacity to aid the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Colorado.

The Viral Vector Manufacturing market is segmented and analyzed as given below:

By Type

  • Retroviral Vectors
  • Lentiviral Vectors
  • Adenoviral Vectors
  • Others

By Application

  • Vaccinology
  • Gene Therapy

By End-User

  • Pharmaceutical & Biotechnology Companies
  • Research Institutes
  • Contract Research Organization

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Thailand
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. VIRAL VECTOR MANUFACTURING MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Retroviral Vectors
  • 5.3. Lentiviral Vectors
  • 5.4. Adenoviral Vectors
  • 5.5. Others

6. VIRAL VECTOR MANUFACTURING MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Vaccinology
  • 6.3. Gene Therapy

7. VIRAL VECTOR MANUFACTURING MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical & Biotechnology Companies
  • 7.3. Research Institutes
  • 7.4. Contract Research Organizations

8. VIRAL VECTOR MANUFACTURING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. UAE
    • 8.5.2. Saudi Arabia
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Thailand
    • 8.6.6. Indonesia
    • 8.6.7. Taiwan
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Sirion-Biotech GmbH
  • 10.2. Vigene Biosciences
  • 10.3. Batavia Biosciences B.V.
  • 10.4. Virovek
  • 10.5. Lonza
  • 10.6. Vector Biolabs
  • 10.7. Cobra Biologics
  • 10.8. MaxCyte, Inc.
  • 10.9. Genelux
  • 10.10. BioNTech SE